Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 1-Year High - Should You Buy?

Key Points

• Amneal Pharmaceuticals' stock reached a new 52-week high of $10.38 amid trading, following a previous close of $10.01.
• Analysts have a consensus rating of "Buy" for AMRX, with JPMorgan increasing their target price from $12.00 to $14.00.
• The company recently reported an earnings per share (EPS) of $0.23, exceeding analysts’ expectations of $0.17.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $10.37 and last traded at $10.38, with a volume of 909596 shares traded. The stock had previously closed at $10.01.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on AMRX shares. JPMorgan Chase & Co. increased their target price on Amneal Pharmaceuticals from $12.00 to $14.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a report on Friday, June 6th. They issued a "buy" rating and a $12.00 target price for the company. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $12.00.

Amneal Pharmaceuticals Trading Up 3.7%

The stock has a market capitalization of $3.26 billion, a price-to-earnings ratio of 1,039.04 and a beta of 1.19. The stock has a fifty day moving average of $9.21 and a two-hundred day moving average of $8.27.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Equities analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Insider Transactions at Amneal Pharmaceuticals

In other news, Director John Kiely sold 32,000 shares of the firm's stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $9.23, for a total value of $295,360.00. Following the transaction, the director directly owned 225,433 shares in the company, valued at $2,080,746.59. This trade represents a 12.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Nikita Shah sold 114,492 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $9.66, for a total value of $1,105,992.72. Following the completion of the transaction, the executive vice president owned 152,743 shares in the company, valued at $1,475,497.38. This represents a 42.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 609,206 shares of company stock valued at $5,700,625 over the last 90 days. 17.45% of the stock is currently owned by corporate insiders.

Institutional Trading of Amneal Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in AMRX. Nuveen LLC acquired a new stake in Amneal Pharmaceuticals during the 1st quarter worth $19,581,000. Rubric Capital Management LP raised its stake in Amneal Pharmaceuticals by 9.1% during the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company's stock worth $94,737,000 after buying an additional 974,355 shares during the period. Woodline Partners LP raised its stake in Amneal Pharmaceuticals by 165.2% during the 1st quarter. Woodline Partners LP now owns 1,504,095 shares of the company's stock worth $12,604,000 after buying an additional 937,035 shares during the period. Vanguard Group Inc. raised its stake in Amneal Pharmaceuticals by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock worth $132,092,000 after buying an additional 920,758 shares during the period. Finally, Acadian Asset Management LLC raised its stake in Amneal Pharmaceuticals by 51.3% during the 1st quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company's stock worth $21,759,000 after buying an additional 880,471 shares during the period. Institutional investors and hedge funds own 31.82% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.